Navigation Links
Pancreas-targeted siRNA In Vivo Transfection Kit from Altogen Biosystems
Date:3/6/2012

LAS VEGAS, March 6, 2012 /PRNewswire/ -- Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals. This in vivo reagent is designed for targeted siRNA delivery into pancreas, however it is also compatible for transfection of any negatively charged molecules including RNA, DNA, proteins, and small molecules.

The pancreas is very important hormone-secreting organ in the human body. Pancreatic diseases include: Diabetes, pancreatitis, cystic fibrosis, and neoplasms. Pancreatic cancer is the fourth leading cause of cancer death in the United States with a lowest survival rate of its victims than any other form of cancer. Researchers in diabetes, pancreatic cancer, and other pancreas disorders, are focused on discovering and developing new therapeutics for patients. Testing novel compounds require efficient and targeted delivery of pharmaceuticals into pancreas tissue (known as in vivo transfection).

Pancreas-targeted siRNA In Vivo Transfection Kit enables researchers to utilize in vivo transfection method to introduce DNA, RNA, and other molecules into pancreas cells. This liposome-based technology makes it possible to cross the cellular barriers and deliver genetic material, or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.  Highly efficient targeted delivery of biomolecules to pancreas tissue is achieved via multiple administration routes: intravenous, intratumoral, intraperitoneal, or subcutaneous.

About Altogen Biosystems

Altogen Biosystems (www.altogen.com) is a life sciences company located in Las Vegas, Nevada. Altogen Biosystems specializing in the development of pre-optimized in vitro transfection reagents and in vivo delivery systems, transfection products and services. Altogen Labs (www.altogenlabs.com) is a GLP-compliant laboratory contract research organization.  The company offers pre-clinical research and biology CRO services including: xenograft animal models (cancer), cryopreservation and cell banking services, generation of stable cell lines, gene silencing RNAi services, tissue-targeted in vivo siRNA and DNA delivery services, custom liposome encapsulation, and cell-based assay development. 

Link: Pancreas-targeted siRNA In Vivo Transfection Kit  - http://www.altogen.com/Pancreas-In-Vivo-Transfection-Reagent-mouse-rat-tumor-animal-model-sirna-dna-protein-pancreas-invivo-delivery.php


'/>"/>
SOURCE Altogen Biosystems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics
4. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
5. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
6. Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
7. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
8. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
9. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
10. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
Breaking Medicine News(10 mins):